COVID-19 Neurological Disease: a Global Meta-Analysis and Prospective Case Control Study in Brazil, India and Malawi.

点击翻译按钮获取中文摘要

Most patients with COVID-19 have cough and breathing problems. However, we are now seeing patients with neurological (brain) disease too. We want to understand why to help us improve treatment. 1. Doctors are publishing reports of single or small groups of patients, or registries. These describe patients in different ways using different definitions. This means it is hard to see the full range of brain disease. Through our global network, we will pull together data from all patients (published or not) to produce a single large report. 2. We want to understand why some patients with COVID-19 get neurological disease. We will therefore conduct a study in Brazil, India and Malawi. We will compare patients with and without neurological disease, to identify risk factors for neurological disease. We are especially interested in those factors which could be treated, such as lack of oxygen in the blood. 3. We will also look at outcomes for neurological patients, again looking at factors associated with a bad outcome. 4. We have a strong Patient, Public and Community Engagement and Involvement Programme, and good links to the World Health Organisation (WHO) and national policymakers. These will help to ensure our information rapidly informs clinical guidelines to improve patient management and save lives. 5. We will also train doctors and scientists in such research to improve their knowledge and skills, and build capacity.